Viral surface proteins

Viral surface proteins, including envelope glycoproteins and capsid proteins, are essential structural components that facilitate viral attachment, fusion, and entry into host cells (PubMed: 33045431). The target "Viral surface proteins – non-specific substrate proteolysis" refers to a therapeutic approach where broad-spectrum proteases are used to enzymatically degrade these proteins, thereby neutralizing the virus's infectivity (PubMed: 33548650). This mechanism is considered non-specific because the enzymes, such as trypsin or bromelain, cleave various peptide bonds within the viral proteins rather than targeting a single specific epitope or active site. Such treatments are typically applied topically, such as in nasal or oral sprays, to reduce the viral load in the upper respiratory tract during the early stages of infection (PubMed: 32812052). While effective against a wide range of viruses, including SARS-CoV-2 and influenza, the primary challenge is ensuring that the proteolysis does not significantly damage host tissues or trigger adverse immune responses (PubMed: 34534954). Consequently, this target represents a physical deactivation strategy rather than a traditional pharmacological inhibition of a viral enzyme.

Other names

Viral envelope proteinsViral capsid proteinsViral surface glycoproteinsViral attachment proteins

Non-specific proteolytic degradation of viral surface proteins, leading to structural disruption and neutralization of viral infectivity.